Share this article on:

Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study

Friis-Møller, Nina; Weber, Rainera; Reiss, Peterb; Thiébaut, Rodolphec; Kirk, Oled; Monforte, Antonella d'Arminioe; Pradier, Christianf; Morfeldt, Lindag; Mateu, Silviah; Law, Matthewi; El-Sadr, Wafaaj; De Wit, Stephank; Sabin, Caroline Al; Phillips, Andrew Nl; Lundgren, Jens Dfor the DAD study group

Clinical Science

Objective: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies.

Design: Baseline data from 17 852 subjects enrolled in DAD, a prospective multinational cohort study initiated in 1999.

Methods: Cross-sectional analyses of CVD risk factors at baseline. The data collected includes data on demographic variables, cigarette smoking, diabetes mellitus, hypertension, dyslipidaemia, body mass index, stage of HIV infection, antiretroviral therapy.

Results: Almost 25% of the study population were at an age where there is an appreciable risk of CVD, with those receiving a protease inhibitor (PI) and/or non-nucleoside reverse transcriptase inhibitor (NNRTI) tending to be older. 1.4% had a previous history of CVD and 51.5% were cigarette smokers. Increased prevalence of elevated total cholesterol (≥ 6.2 mmol/l) was observed among subjects receiving an NNRTI but no PI [odds ratio (OR), 1.79; 95% confidence interval (CI), 1.45–2.22], PI but no NNRTI (OR, 2.35; 95% CI, 1.92–2.87), or NNRTI + PI (OR, 5.48; 95% CI, 4.34–6.91) compared to the prevalence among antiretroviral therapy (ART)-naive subjects. Subjects who have discontinued ART as well as subjects receiving nucleoside reverse transcriptase inhibitors had similar cholesterol levels to treatment-naive subjects. Higher CD4 cell count, lower plasma HIV RNA levels, clinical signs of lipodystrophy, longer exposure times to NNRTI and PI, and older age were all also associated with elevated total cholesterol level.

Conclusion: HIV-infected persons exhibit multiple known risk factors for CVD. Of specific concern is the fact that use of the NNRTI and PI drug classes (alone and especially in combination), particularly among older subjects with normalized CD4 cell counts and suppressed HIV replication, was associated with a lipid profile known to increase the risk of coronary heart disease.

From the DAD Coordinating Centre, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark, the aSwiss HIV Cohort Study (SHCS), Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland, bATHENA, Department of Medicine and Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, cAquitaine, Institut de Santé Publique, d'Epidémiologie et de Développement – Inserm U330, Bordeaux University Hospital, Bordeaux, France, dEuroSIDA, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark, eICONA, Department of Infectious Diseases, L Sacco Hospital, University of Milan, Milan, Italy, fNice Cohort, Service des Maladies Infectieuses et Tropicales et Medicine Interne, C.H.U. Nice Hopital de l'Archet, Nice, France, gHivBivus, Department of Infectious Diseases, Karolinska Hospital, Stockholm, Sweden, hBASS, Department of Clinical Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain, iAHOD, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia, jCPCRA, Division of Epidemiology, Columbia University School of Public Health, New York, USA, the kBrussels St. Pierre Cohort, Department of Infectious Diseases, C.H.U. Saint Pierre Hospital, Brussels, Belgium, and the lRoyal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College, London, UK. *See Appendix.

Correspondence to N. Friis-Møller, DAD Coordinating Centre, Copenhagen HIV Programme, Section 044, Hvidovre University Hospital, 2650 Copenhagen, Denmark. e-mail:

Received: 14 March 2002; revised: 20 November 2002; accepted: 13 January 2003.

Back to Top | Article Outline


The combination of three or four drugs from any of the three available classes that can inhibit the replication of HIV [nucleoside analogue reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI)], has lead to a dramatically improved outcome from this chronic infection [1–6].

While the benefits of highly active antiretroviral therapy (HAART) have revolutionized the care of HIV-infected patients, frequent and sometimes severe treatment-associated metabolic side effects have been observed [7]. Several well known important risk factors for cardiovascular disease (CVD) can be induced and/or enhanced by PI-containing HAART [8]. These include increases in serum total cholesterol (particularly an increase in the atherogenic non-high density lipoprotein (non-HDL) cholesterol [9]) and triglycerides, as well as impaired glucose tolerance/overt diabetes mellitus associated with increased insulin resistance [10], and possibly arterial hypertension [11,12]. However, whether and how soon these antiretroviral therapy-induced abnormalities may result in a clinically detectable increased risk of CVD remains unknown, as does the impact of the underlying HIV infection per se. The available data are largely limited to case reports of myocardial infarctions in young PI-treated HIV- infected patients [13–17]. A meta-analysis of the immediate risk of myocardial infarction in randomized trials comparing PI and non-PI containing regimens, demonstrated no significant differences between the regimens [18], and presented retrospective studies have provided conflicting evidence [19–24].

To gain further insight into the risk of treatment-associated CVD, a multinational, tri-continental collaboration between ongoing HIV cohort studies was initiated in December 1999 (the DAD study, Data collection on Adverse events of anti-HIV Drugs [25]) with the objectives of detecting the incidence of myocardial infarction and stroke, and of identifying whether exposure time to the agents contained in antiretroviral drug regimens is independently associated with the risk of developing these cardiovascular events. The working hypothesis of the study is that anti-HIV drugs may accelerate the atherosclerotic process and, by doing so, increase the risk of CVD including myocardial infarction. The study is powered to detect a twofold increased risk of myocardial infarction, and will follow a cohort of more than 20 000 HIV-infected patients at various stages of infection and therapy prospectively for a minimum of 2 years.

The objectives of the present analyses were to determine the proportion of patients with an elevated risk profile for CVD at the time of inclusion into the DAD study, and to identify factors associated with these increased risk profiles, particularly with regards to the type and duration of antiretroviral therapy.

Back to Top | Article Outline



The DAD study is an observational study formed by the collaboration of previously established HIV cohorts. Eleven cohorts [26–36] participate and contribute data on more than 20 000 HIV infected patients followed at 188 clinics in 20 countries situated in Europe, USA and Australia (Table 1 and Appendix).

Table 1

Table 1

Back to Top | Article Outline

Data collection

Patients are followed prospectively during visits to out-patient clinics scheduled as part of regular medical care. Eligible patients are all under active follow-up at the time of initiation of the DAD protocol, irrespective of antiretroviral treatment status. Patients were enrolled into DAD consecutively as they were seen in the clinic from the time the DAD study was implemented in each of the participating cohorts. The first cohorts started to include patients in December 1999, and all patients were included prior to 1 April 2001.

At enrolment and at least every 8 months thereafter standardized data collection forms are completed at the sites providing information from physical examination, patient interview and patient case notes, concerning family history of coronary heart disease, patients’ prior history of CVD and diabetes, cigarette smoking, blood pressure, therapy for diabetes mellitus, lipid-lowering and anti-hypertensive therapy, the presence of clinical signs of lipodystrophy and serum lipid levels (including total- and HDL-cholesterol, triglycerides, and information on fasting conditions). Further, all cumulative data characterizing the patient's underlying HIV infection since inclusion in any of the individual cohorts are collected, including information on demography, antiretroviral therapy, CD4 cell counts and HIV viral loads. Dates of diagnosis of all AIDS-defining diseases are recorded, using the 1993 clinical definition of AIDS from the Centers for Disease Control and Prevention [37]. All collected information is transformed into a standardized format and merged into a central data-set.

Back to Top | Article Outline


HIV laboratory parameters

In various analyses, CD4 cell count was stratified in strata of 100 × 106 (cells/l) or assessed as a continuous variable (log2 transformed). Similarly, HIV RNA was stratified in strata of: ≤ 500, 501–10 000, 10 001–100 000, and > 100 000 copies/ml, and also assessed as a continuous variable (log10 transformed).

Back to Top | Article Outline

Antiretroviral therapy

Six categories were predefined based on current use of antiretroviral therapy regimen at the time of enrolment into the DAD study. These are: (i) naive; (ii) treatment-experienced, but not currently receiving antiretroviral therapy; (iii) currently receiving only NRTI; (iv) currently receiving NNRTI and NRTI but not PI; (v) currently receiving PI and NRTI but not NNRTI; or (vi) currently receiving PI, NNRTI and NRTI.

Previous antiretroviral therapy exposure was modelled as cumulative time spent using each of the three drug classes.

Back to Top | Article Outline

CVD risk factors

The grouping of the risk factors assessed was defined prior to the initiation of the analysis. CVD risk factors were assessed as dichotomous categorical variables, where the cut-off levels chosen were conservative estimates of ‘high risk’ based on levels used for risk scoring in the background population [38–41]. The specification of risk factors is as follows. (i) Dyslipidaemia: defined as elevated total cholesterol ≥ 6.2 mmol/l (240 mg/dl), and/or decreased HDL-cholesterol ≤ 0.9 mmol/l (35 mg/dl), and/or elevated triglycerides ≥ 2.3 mmol/l (200 mg/dl). [The cut-offs applied are based on cut-offs for high risk for CVD in the NCEP guidelines.] (ii) Older age: age ≥ 45 years for men and ≥ 55 for women. (iii) Family history of coronary heart disease: first-degree relative with myocardial infarction before age 50. (iv) Previous CVD: patients’ own previous experience of myocardial infarction and/or stroke. (v) Hypertension: elevated systolic blood pressure ≥ 150 mmHg and/or elevated diastolic blood pressure ≥ 100 mmHg, or usage of anti-hypertensive drugs. (vi) Diabetes: history of diabetes or usage of anti-diabetic therapy. (vii) Body mass index (BMI) was stratified in four categories: underweight (BMI, < 18 kg/m2), normal weight (BMI, 18–26 kg/m2), overweight (BMI, 26.1–30 kg/m2) and obesity (BMI, > 30 kg/m2). Obesity was considered a cardiovascular risk factor. (viii) Smoking: current cigarette smoking at inclusion in the DAD study. (ix) Presence of clinical lipodystrophy was defined as either characteristic fat loss (from the face and/or extremities), central fat gain (abdominal and/or cervicodorsal) or mixed (at least one sign each of fat loss and central fat gain), as judged by the treating physician.

Back to Top | Article Outline

Statistical analyses

Prevalence of single risk factors was calculated for the groups of patients for which data were available. Based on the observed prevalence, dyslipidaemia, diabetes, hypertension and lipodystrophy were further assessed as outcome variables in logistic models.

Univariable chi-squared and Kruskal–Wallis tests were used to compare categorical and continuous baseline demographic, clinical and laboratory characteristics between antiretroviral regimen categories. Association of CVD risk factors with antiretroviral therapy, demographic, clinical and laboratory parameters were tested in univariable logistic regression models. Multivariable logistic regression was then performed to identify parameters independently associated with the presence of CVD risk factors. The multivariable model included all parameters significantly associated with the risk factor assessed, at a level of P < 0.05 in the univariable model. For the main associations, the outcomes of the logistic models were tested in linear models, where the outcome variables were modelled as continuous variables.

From the literature it is known that total cholesterol levels are not significantly influenced by fasting status and HDL-cholesterol is influenced only slightly [42–44]. Although triglycerides are influenced by fasting, their daily fluctuation does not have a simple relationship with intake of meals [45]. In order to consider the impact of fasting status on the results, sensitivity analyses were repeated separately for fasting and non-fasting triglyceride measurements. Similarly, and for all lipid measurements, sensitivity analyses were performed to assess associations among the cohorts with less missing data. The associations of the primary analyses were reproduced by the sensitivity analyses; these results have generally not been included in this report.

All analyses were performed using Statistical Analysis System (SAS) version 6.12 (SAS Institute Inc, Cary, North Carolina, USA).

Back to Top | Article Outline



By April 2001, the central database contained information on 17 852 patients enrolled in DAD from nine of 11 participating cohorts. The patient characteristics are shown in Tables 1, 2 and 3. Seventy-six percent were male, the median age was 39 years [inter quartile range (IQR), 34–45], 25% previously had AIDS. Mode of HIV acquisition was homosexual contacts in 43%, heterosexual contacts in 28% and injecting drug use in 23%. The median CD4 cell count was 430 × 106 cells/l (IQR, 270–621 × 106 cells/l) and median plasma HIV RNA was below 500 copies/ml (IQR, < 500–4800 copies/ml). These variables varied by cohort (Table 1).

Table 2

Table 2

Table 3

Table 3

Two cohorts (CPCRA and the Brussels St. Pierre cohort) were included later in the DAD study and their patient characteristics at baseline not analysed in this manuscript.

Back to Top | Article Outline

Antiretroviral therapy

At enrolment, 13% of the study population were antiretroviral therapy naive, 6% were previously exposed, but not currently receiving any antiretroviral therapy, 11% were receiving a regimen containing NRTI only, 20% were receiving NNRTI-based therapy, 43% PI-based therapy and 7% were on a regimen containing all three drug classes. Overall, 72% of the study population had at any one time been exposed to PI with a median exposure time of 2.5 years (IQR, 1.5–3.2 years), 36% had ever been exposed to NNRTI with a median exposure time of 0.9 years (IQR, 0.5–1.5 years) and 87% had ever been exposed to NRTI with a median exposure of 3.2 years (IQR, 2.0–4.7 years) (Table 2).

Back to Top | Article Outline

CVD risk factors and association with antiretroviral drugs and duration of therapy

CVD risk factors were prevalent in the study population (Table 3). Almost 25% of the study population was in an age group constituting a CVD risk factor by our definition, with the highest prevalence among patients receiving PI, NNRTI or both of these drug classes. 11.4 % had a family history of coronary heart disease with no significant difference between the antiretroviral therapy groups, and 1.4% had a previous history of CVD, with the highest prevalence in the group of patients receiving a regimen containing both PI and NNRTI. More than half of the study population were current cigarette smokers, with the highest prevalence among the naive patients and patients not currently receiving antiretroviral therapy.

Back to Top | Article Outline


More than 8% of the study population had hypertension. In a univariable logistic model, using the antiretroviral therapy-naive group as reference, regimens containing NNRTI, PI or both drug classes were associated with an increased risk of being hypertensive (Table 4). But after adjustment for other factors which univariably were associated with the presence of hypertension, the associations with antiretroviral therapy disappeared or were reversed (Table 4). This was explained mainly by a strong correlation of hypertension with other factors (age, sex and BMI).

Table 4

Table 4

Back to Top | Article Outline


The overall prevalence of diabetes was 2.5%. In a univariable model, all regimens were associated with an increased risk of diabetes when compared with naive patients (Table 4). After adjustment for other factors, current therapy with a regimen containing NNRTI or NNRTI + PI remained marginally independently associated with the presence of diabetes.

Back to Top | Article Outline

Serum total cholesterol

The association of antiretroviral therapy with lipid levels is shown in Table 3. Assessed from median cholesterol levels (Table 3) and in univariable models (Table 4), patients currently using regimens containing NNRTI + NRTI, PI + NRTI or all three drug classes combined were at increased risk of having a high total cholesterol when compared with naive patients, with the highest risk among patients receiving a regimen containing all three drug classes. This pattern remained unchanged after controlling for other risk factors (Table 4). Subjects receiving NRTI only as well as subjects who had discontinued antiretroviral therapy have similar total cholesterol levels to naive subjects (regardless of duration of previous exposure to any of the drug classes), the latter suggestive of a reversible drug effect on total cholesterol level.

We further examined the effect of duration of exposure to the drug classes. As current and previous antiretroviral therapy exposures were highly correlated, these parameters were fitted in separate models. In a univariable logistic model for cumulative antiretroviral therapy exposure time, the OR for elevated total cholesterol was 1.00 (IQR, 0.98–1.02; P = 0.81), 1.39 (IQR, 1.31–1.47; P < 10−4) and 1.42 (IQR, 1.38–1.47; P < 10−4) per year of exposure to NRTI, NNRTI and PI, respectively. After controlling for other risk factors for dyslipidaemia, these associations remained essentially unchanged (data not shown; the model included sex, age, smoking, family history of coronary heart disease, previous cardiovascular disease, BMI, HIV transmission category, CD4 cell count, HIV RNA and duration of NRTI, NNRTI and PI therapy).

Among patients who currently or previously were exposed to antiretroviral therapy, level of immunodeficiency and plasma HIV RNA were independently associated with elevated total cholesterol after adjustment for other factors, including duration of antiretroviral therapy. The association was present within each antiretroviral therapy regimen group (Fig. 1). Overall, the adjusted risk of having elevated total cholesterol increased by 24% per twofold increase in CD4 cell count [OR, 1.24 (IQR, 1.18–1.30) per log2CD4, P < 10−4], thus the highest risk of elevated cholesterol is among patients with preserved or regained immunity (Fig. 1a). Of note, there was no association of CD4 cell count with total cholesterol in treatment-naive patients. In all antiretroviral therapy groups, and also in the group of antiretroviral therapy-naive patients, higher HIV viral load was associated with a decreased risk of elevated total cholesterol (Fig. 1b), overall the adjusted OR was 0.70 (IQR, 0.65–0.75), P < 10−4, per 1 log10 increase in HIV RNA.

Fig. 1.

Fig. 1.

Back to Top | Article Outline

Serum triglycerides

The prevalence of elevated triglycerides was 28.4% among patients with fasting values and 35.4% for the non-fasting measurements (36% of measurements were fasting values, 24% non-fasting and the remaining lacked information regarding fasting status). The associations of antiretroviral treatment with elevated triglycerides resembled the associations seen with total cholesterol (Table 4), and were also similar within each group, when fasting and non-fasting measurements were tested separately (data not shown).

In a univariable logistic model for cumulative antiretroviral drug exposure time, the OR for elevated triglycerides was 1.05 (IQR, 1.03–1.07), 1.28 (IQR, 1.21–1.35) and 1.38 (IQR, 1.34–1.42) per year of exposure to NRTI, NNRTI and PI respectively (all, P < 10−4). In the multivariable model these associations remained essentially unchanged (data not shown).

The association with CD4 cell count and HIV viral load differed between regimens. Among patients who were antiretroviral therapy-naive, previously exposed, but not currently receiving any antiretroviral therapy, or currently receiving a regimen containing NRTI only, the adjusted risk of elevated triglycerides increased with increasing HIV RNA [OR, 1.18 (IQR, 1.07–1.31) per 1 log10 increase; P = 0.001], whereas there was no significant association with CD4 cell count [OR, 1.06 (IQR, 0.99–1.13) per twofold increase; P = 0.12].

Among patients receiving NNRTI, PI or a regimen containing both drug classes, the risk of elevated triglycerides increased with increasing HIV viral load [adjusted OR, 1.13 (IQR, 1.06–1.21) per 1 log10 increase; P < 10−4] and also increased with increasing CD4 cell count [OR, 1.20 (IQR, 1.15–1.26) per twofold increase in CD4 cell count; P < 10−3].

Back to Top | Article Outline

Serum high density lipoprotein (HDL)-cholesterol

All regimens were associated with an increased risk of low HDL-cholesterol except regimens containing NNRTI, when compared to naive subjects (Table 4). In a univariable logistic model for cumulative antiretroviral drug exposure time, the OR for decreased HDL-cholesterol per year of exposure to NRTI, NNRTI and PI respectively, was 1.08 (IQR, 1.05–1.11; P < 10−4), 0.87 (IQR, 0.80–0.95; P < 0.002) and 1.01 (IQR, 0.97–1.06; P = 0.53). The multivariable model showed similar associations.

The associations of CD4 cell count and HIV viral load were similar for the absolute value of HDL-cholesterol as for total cholesterol, i.e., the risk of having decreased HDL-cholesterol is highest among patients with low CD4 cell count and high HIV viral load.

Back to Top | Article Outline

Body composition

In all regimen groups there were few obese patients (Table 3), with a slightly higher prevalence among treatment-naive (4.8%) patients than in other groups. As would be expected, antiretroviral therapy was highly associated with the presence of clinical lipodystrophy, with the highest risk among patients receiving a regimen containing all three drug classes (Tables 3 and 4). Patients exposed for a longer time to the antiretroviral drug classes tended to have a higher prevalence of lipodystrophy at baseline (data not shown). Using the composite definition of lipodystrophy, there was no association between BMI and lipodystrophy (data not shown).

When assessed as an explanatory variable, lipodystrophy was associated with the presence of several of the CVD risk factors discussed above. In a multivariable model including the total study population, and adjusting for co-variables as listed in Table 4, the adjusted OR for the association of lipodystrophy with elevated total cholesterol was 1.56 (IQR, 1.41–1.72; P < 10−4), elevated triglycerides 2.16 (IQR, 1.98–2.37; P < 10−4) and decreased HDL 1.53 (IQR, 1.35–1.73; P < 10−4). The presence of lipodystrophy was associated with an increased risk of hypertension and diabetes [OR, 1.34 (IQR, 1.17–1.54) and 2.05 (IQR, 1.63–2.58), respectively; both P < 10−4].

Back to Top | Article Outline


In the DAD population we have observed a high prevalence of multiple risk factors for CVD, particularly among patients currently receiving an antiretroviral therapy regimen containing all three drug classes. DAD has the strength of having included more than 20 000 patients with details concerning CVD risk factors and thereby is by far the largest study conducted to date which addresses CVD risk factors in HIV infection. A novel finding was that regimens containing drugs from both the PI and NNRTI classes were associated with the highest prevalence of dyslipidaemia, suggestive of a possibly additive effect of combinations of drugs from these drug classes. Furthermore, we observed that hypercholesterolaemia was associated with a higher CD4 cell count (in antiretroviral-treated people), a lower HIV plasma viral load, the presence of clinical signs of lipodystrophy and older age.

Dyslipidaemia was most strongly correlated with antiretroviral regimens currently being used, and less with a history of previous exposure to the different drug classes. This finding corresponds with previous reports, in which the dyslipidaemia associated with PI occurred shortly after beginning therapy (in the fraction of patients prone to develop this adverse effect) [8,46] and the rate of increase in lipid levels abated within months of initiation of the drugs. It is also consistent with studies that have shown that switch from PI to NNRTI-based or NRTI-only regimens is associated with attenuation or resolution of dyslipidaemia [47] within a short period of time (i.e., a few months). However, the cumulative time of exposure to various antiretroviral drug classes (with the concomitant risk of raised lipid levels) is likely to be relevant when predicting the risk of future CVD.

The association between PI therapy and elevated levels of total cholesterol and serum triglycerides has been noted previously in smaller cohort studies. The average increases in lipid levels in the largest series published to date [9,10,48,49], comparing levels during PI therapy with either pre-therapy levels or levels in PI-naive HIV-infected patients, were 28% for total cholesterol and 96% for triglycerides. We observed no difference in risk of low HDL-cholesterol among patients treated with PI, NRTI or not currently receiving antiretroviral therapy, and patients in these groups all had lower HDL-cholesterol levels than treatment-naive individuals. Consistent with most other studies, duration of PI therapy did not influence the level of HDL-cholesterol [49], whereas duration of NRTI was associated with a higher risk of low HDL-cholesterol.

An increase in total cholesterol with no increase in the HDL fraction is of particular concern, because it implies an elevation of the atherogenic non-HDL-cholesterol. The risk of elevated total cholesterol was increased per additional drug included in the regimen, and for longer exposure time to PI. Additional analysis to assess possible differences between individual PI is underway to examine these associations in more detail [50].

In contrast with previous observations of an association of PI use and dyslipidaemia, our finding of an association between NNRTI-containing regimens and dyslipidaemia has not been widely investigated. Phase I studies of efavirenz in HIV-uninfected subjects revealed increases in total cholesterol levels of 10–20% in some subjects [51], and no differences between different NNRTI were reported in HIV-infected individuals [52]. In concordance with our results, an increase in (protective) HDL-cholesterol with NNRTI has recently been reported [53,54]. More detailed analyses to assess possible differences between individual NNRTI are ongoing [55].

Consistent with previous reports, NRTI-only therapy was not associated with elevated cholesterol [52,56]. With regards to triglycerides, recent studies have indicated differences among drugs in the NRTI drug class, with a higher propensity for high triglyceride levels associated with stavudine use [56,57]. Future analyses from the DAD study will further assess differences between individual drugs within the NRTI drug class.

So far, few studies have examined factors which predispose HIV-infected patients to treatment-associated lipid abnormalities [58–60]. We have identified several factors that are significantly associated with the presence of dyslipidaemia in HIV infected subjects receiving antiretroviral therapy. We found a strong association between elevated total cholesterol level and higher CD4 cell counts, which was present within each treatment category but not in the antiretroviral therapy-naive group. Nevertheless, within each CD4 cell count stratum, the effect of antiretroviral therapy was clearly observed, which indicates that the effect of antiretroviral substances certainly cannot solely be explained by a reversal to ‘normal’ pre-disease cholesterol levels as a result of improved cellular immunity. The CD4 cell count level remained independently associated with elevated total cholesterol also after adjustment for duration of treatment. This does not rule out, however, that the observed association may still – at least in part – be due to residual confounding of the effect of antiretroviral therapy, either directly via a dose–response effect (i.e., higher CD4 cell count and lower plasma viral load are surrogates of better adherence and hence higher exposure to causative drugs) or indirectly via lowering HIV-RNA levels (see below).

The level of HDL-cholesterol, although to a lesser extent, likewise increased with more conserved cellular immunity, consistent with observations in the pre-HAART era [61], while no clear association was observed for levels of triglycerides after adjusting for therapy.

For total cholesterol, the association with HIV viral load was the inverse of the association with CD4 cell count. Thus we found increasing levels of total cholesterol with lower HIV RNA, and similarly for HDL-cholesterol. The latter has also been reported from other studies [62]. Conversely, overall and after adjustment for other factors, levels of triglycerides increased with increasing HIV viral load, consistent with the findings in the pre-PI era of elevated triglycerides linked to HIV disease progression [63].

Subjects already exposed to other risk factors for CVD are likely to have an accelerated course of atherosclerosis and the clinical complications hereof, given the known synergistic effects of different CVD risk factors [38]. In the DAD study, we have observed a high prevalence of other known and potential CVD risk factors among patients receiving either PI or NNRTI, including cigarette smoking, diabetes, hypertension and altered body composition.

The overall prevalence of diabetes mellitus in the DAD study was 2.5% and varied between regimens, from 1.1% in patients not currently receiving antiretroviral therapy to 4.3% in patients receiving PI and NNRTI. This is consistent with other studies which have shown an association between impaired glucose tolerance, diabetes mellitus and use of PI [8,9,48]. The prevalence of diabetes in PI-treated HIV patients has been reported to be in the range of 2–8%, with the highest detection rate in studies based on performance of oral glucose tolerance testing. In the setting of our observational study, in which oral glucose tolerance testing is not mandated and the diagnosis will mainly rely on measuring repeated elevated fasting blood sugar, the prevalence of diabetes is likely to be underestimated.

Data on the prevalence of hypertension in HIV patients are limited. A few studies have reported an increased prevalence of hypertension in PI treated patients [11,12] or in conjunction with lipodystrophy [64]. In our study, the associations between antiretroviral drug regimens and hypertension in univariable logistic models were no longer present after adjustment for other factors associated with hypertension. Thus, our data do not support a concern that HIV treatment per se is likely to induce hypertension.

Consistent with current knowledge [10], the use of antiretroviral therapy was strongly associated with the presence of lipodystrophy. Furthermore, there was a marked association between dyslipidaemia and several of the other CVD risk factors on the one hand and clinical lipodystrophy on the other. Such associations do not necessarily suggest a particular aetiology of lipodystrophy, but rather describe a clinical phenomenon, as the definition of lipodystrophy in the present analyses includes all clinical presentation of the syndrome, when in fact the various fat re-distribution patterns may represent separate entities with different aetiology [65]. Clinical lipodystrophy – i.e., fat redistribution – is associated with presence of several known metabolic risk factors for CVD, and therefore the lipodystrophy syndrome would also be expected to be associated with an increased risk of CVD.

Whether the presence of fat redistribution in itself – by way of abnormal fat loss and/or gain – represents an independent risk for CVD remains unresolved. A large collaboration is ongoing with the purpose of establishing a case definition for the lipodystrophy syndrome [66], which will facilitate the evaluation of the different clinical patterns and their possible influence on risk of CVD.

Compared with antiretroviral therapy-naive subjects, those treated with antiretroviral drugs tended to be less obese. Whether this observation is causally related to adverse events caused by the antiretroviral drugs should be investigated further. Obesity is an independent risk factor for CVD in the background population [40,67].

Back to Top | Article Outline

Strengths and limitations

The strength of our results is primarily related to the substantial size of the study population. The diversity of the study population, including patients from a variety of geographical areas and a substantial number of women and minorities, ensures that the study is representative of the HIV infected population in industrialized countries.

The limitations are mainly related to the observational design of the study and the cross-sectional nature of the current analyses. Firstly, the results presented are only associations from which no conclusions regarding causality can or should be drawn. Secondly, due to the observational design of the study, many measurements are expected not to be always conducted in a uniform manner. This includes measurement of blood pressure and laboratory analyses of lipid levels. However, even in the absence of uniform standards for this study, national and international standardization of serum lipid measurements have been accomplished through collaboration of the Centers for Disease Control and Prevention and the World Health Organization, and comparable results can be obtained globally because of these standardization efforts [68]. Thirdly, the relatively high proportion of missing data should be noted (Table 3), which amongst other things implies that the prevalence of the individual risk factors is imprecise. Measures have been taken to complete the collection of pending baseline data during follow-up. Finally, information concerning certain other potential risk factors for CVD was not collected in our study, including genetic factors, physical activity, diet and alcohol consumption.

Back to Top | Article Outline


The present analysis shows that, especially among older patients, the use of potent antiretroviral therapy resulting in more profound virus suppression and more preserved immunity, was associated with a high both relative and absolute risk of exhibiting risk factors for coronary heart disease.

Using these results, work is in progress to model the estimated risk of CVD based on validated algorithms [69]. Such projections assume that the induced risk factors can be directly transposed, which is likely to be a simplification as there presumably will be a time lag from when factors known to accelerate the atherosclerotic process are induced (i.e., when PI and/or NNRTI are started) and until clinical manifestations of atherosclerotic vascular disease will occur. As many of these factors are likely to act synergistically, and as the underlying HIV infection itself and its various manifestations may also contribute, current knowledge does not permit reliable assessment of the duration of the above mentioned time-lag. However, comparison of the estimated expected with the observed CVD event rate in the DAD study may provide some understanding.

The question as to whether antiretroviral therapy-associated metabolic disorders contribute to premature cardiovascular disease is of major importance for the way HIV infection is clinically managed. If current treatment of HIV infection would indeed be shown to be associated with an increased risk of CVD, such risk of course would need to be balanced against the proven major benefits of therapy. It would likely have implications for considerations concerning the composition of regimens, the timing of initiation of therapy, as well as for the evaluation and use of various pharmaceutical and non-pharmaceutical measures directed at reducing CVD risk. Last but not least it stresses the continued need for developing less toxic and better tolerated effective treatments for HIV infection.

Back to Top | Article Outline


Sponsorship: The ATHENA study was supported by a grant (CURE/97-46486) from the Health Insurance Fund Council, Amstelveen, the Netherlands. The Aquitaine Cohort was supported by a grant from the ‘Agence Nationale de Recherches sur le SIDA’ (ANRS, Action Coordonnée no.7, Cohortes). The BASS study was supported by grants from the ‘Fondo de Investigación Sanitaria’ (FIS 99/0887) and ‘Fundación para la Investigación y la Prevención del SIDA en Espanã’ (FIPSE 3171/00). The EuroSIDA study was supported by grants from the European Commission BIOMED 1 (CT94-1637) and BIOMED 2 (CT97-2713) programs, from Pharmacia & Upjohn, GlaxoSmithKline, Roche and Merck. The ICONA network was supported by an unrestricted educational grant from Glaxo Wellcome, Italy. The Swiss HIV Cohort Study was supported by a grant (3345-062041) from the Swiss National Science Foundation. Support for the DAD study was provided by the ‘Oversight Committee for The Evaluation of Metabolic Complications of HAART', a collaborative committee with representation from academic institutions, the EMEA, the FDA and all pharmaceutical companies with licensed anti-HIV drugs in the US marked, i.e., Abbott, Agouron, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, Pharmacia & Upjohn, Hoffman-La Roche.

Back to Top | Article Outline


1.Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, et al. Declining morbidity and mortality Among patients with advanced Human Immunodeficiency Virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860.
2.Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863–868.
3.Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725–1730.
4.Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381–390.
5.BHIVA writing Committee on behalf of the BHIVA Executive Committee. British HIV association guidelines for the treatment of HIV infected adults with antiretroviral therapy. HIV Med 2000, 1:76–101.
6.Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999, 341:1865–1873.
7.Carr A. Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000, 356:1423–1430.
8.Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353: 2093–2099.
9.Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in hiv patients under treatment with protease inhibitors. AIDS 1999, 13:F63–F70.
10.Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51–F58.
11.Hewitt RG, Thompson MA, Chu A, Hernandez F, Shelton MJ. Indinavir, not nelfinavir, is associated with systemic hypertension when compared to no protease inhibitor therapy. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 658].
12.Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Cadrobbi P. Indinavir and systemic hypertension. AIDS 2001, 15:805–807.
13.Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351:1328.
14.Friedl AC, Jost CH, Schalcher C, Amann FW, Flepp M, Jenni R, et al. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 2000, 14:2790–2792.
15.Karmochkine M. Raguin G. Severe coronary artery disease in a young HIV-infected man With no cardiovascular risk factor who was treated with indinavir. AIDS 1998, 12:2499.
16.Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999, 131: 548.
17.Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998, 351:1959.
18.Coplan P, Cormier K, Japour A. Myocardial infarction incidence in clinical trials of 4 protease inhibitors. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January 2000 [abstract 34].
19.Currier J, Boyd F, Burtcel B, Dezii C, Kawabata H, Lilienfeld D, et al. Accelerated atherosclerosis in men infected with HIV. Antiviral Therapy 2001; 6 (suppl. 4): 36 [abstract 49].
20.Bozzette SA, Ake C, Carpenter A, Bommakanty U, Leung V, Tam H, et al. Cardio- and Cerebrovascular Outcomes with Changing Process of Anti-HIV Therapy in 36,766 US Veterans. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract LB9].
21.Klein D, Hurley LB, Quesenberry CP, Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002, 30:471–477.
22.Holmberg SD, Moorman AC, Tong T, Ward D, Wood K, Greenberg A, et al. Protease inhibitor drug use and adverse cardiovascular events in ambulatory HIV-infected patients. XIV International Conference on AIDS. Barcelona, July 2002 [abstract TuPeB4494].
23.Leport C, Saves M, Ducimetiere P, Le Moal G, Amouyel P, Arveiler D, et al. Coronary heart disease risk (CHD) in French HIV-infected men started on a protease inhibitor (PI)-containing regimen compared to the general population. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 697-T].
24.Mary-Krause M, Cotte L, Partisani M, Simon A, Costagliola D. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 657].
25.Data Collection on Adverse Events of Anti-HIV Drugs; Study documents. 1 March 2000.
26.Lundgren JD, Phillips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:153–160.
27.The Community Programs for Clinical Research on AIDS (CPCRA) is an experienced community-based clinical trials network assessing the effect of available HIV therapies in diverse populations across the spectrum of HIV disease. 2001.
28.Keita-Perse O, Roger PM, Pradier C, Pugliese P, Cottalorda J, Dellamonica P. Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T-cell count? AIDS 1998, 12:F175–F179.
29.d'Arminio, Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000, 14:499–507.
30.Clumeck N, De Wit S, Sommereijns B, Barath A. Cerebral toxoplasmosis over the last 10 years in a 2394 patient cohort in Brussels. Eleventh International Symposium on Infections in the Immunocompromised Host. Halifax, Nova Scotia, Canada, June 2000.
31.Morfeldt L, Åkerlund B, Koppel K, Sundström A, Wiholm BE; Steineck G, et al. The HivBivus Project - a concept for the surveillance of ADRs in HIV-infected patients. AIDS 14 (Suppl 4): abstract p. 166.
32.Mateu S, on behalf of the Barcelona Antiretroviral Surveillance Study (BASS) Group. Multicentre prospective cohort study to evaluate the safety profile of HAART in HIV outpatients: one year follow-up results. Antiviral Ther 1999, 4 (suppl 2):58–59 [Abstract 045].
33.Sudre P, Rickenbach M, Taffe P, Janin P, Volkart AC Francioli, P. Clinical epidemiology and research on HIV Infection in Switzerland: the Swiss HIV Cohort Study 1988–2000. Schweiz Med Wochenschr 2000, 130:1493–500.
34.Jambroes M, Weverling GJ, Reiss P, Danner SA, Jurriaans S, ten Veen JH, et al. HIV-1 Therapy in the Netherlands: virological and immunological response to antiretroviral therapy. Ned Tijdschr Geneeskd 2001, 145:1591–1597.
35.The Australian HIV Observational Database. Rates of Change of Combination Antiretroviral Treatment in Australia. HIV Med 2002; 3(1):28–36.
36.Thiebaut R, Morlat, P, Jacqmin-Gadda H, Neau D, Mercie P, Dabis F, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe D'Epidemiologie Du SIDA En Aquitaine (GECSA). AIDS 2000, 14:971–978.
37.1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR 1992, 41(RR–17):1–19.
38.Wilson PW, D'Agostino, RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.
39.Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. British Hypertension Society Guidelines for Hypertension Management 1999: Summary. BMJ 1999, 319:630–635.
40.Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser 2000, 894:I–253.
41.Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993 269:3015–3023.
42.Quality Assessment of Total Cholesterol Measurements in the WHO MONICA Project. WWW Publications from the WHO MONICA Project. 1999.
43.Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988, 29:469–479.
44.Mayer KH, Stamler J, Dyer AR, Stamler R, Berkson D. Epidemiologic findings on the relationship of time of day and time since last meal to five clinical variables: serum cholesterol, hematocrit, systolic and diastolic blood pressure, and heart rate. Prev Med 1978, 7:22–27.
45.Cooper GR, Myers GL, Smith, SJ, Sampson EJ. Standardization of lipid, lipoprotein, and apolipoprotein measurements. Clin Chem 1988 34:B95–105.
46.Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51–57.
47.Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, et al. Impact of switching from Human Immunodeficiency Virus Type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000, 31:1266–1273.
48.Walli R, Herfort O. Michl GM, Demant T, Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 2:F167–F173.
49.Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999, 100:700–705.
50.Pradier C, Sabin C, Friis-Møller N, Weber R, Reiss P, d'Arminio Monforte A, et al. Lipid profiles on therapy with PI. The D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) Study. Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, November 2002 [abstract PL12.1].
51.DuPont Pharmaceuticals. Sustiva Prescribing Information. 2000.
52.Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. J Acquir Immune Defic Syndr 2000, 24:310–315.
53.Becker S, Rachlis A, Gill J, Dejesus E. Successful substitution of protease inhibitors with efavirenz in patients with undetectable viral loads - a prospective, randomised, multicenter, open label study (DMP 049). Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 20].
54.van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001 15:2407–2414.
55.Leth FV, Friis-Møller N, Weber R, d'Arminio Monforte A, Kirk O, Thiebaut R, et al., for the DAD study group. Distinguishable lipid profiles between PI and NNRTI therapy may carry different risk of cardiovascular disease (CVD). Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 34].
56.Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002, 29:21–31.
57.Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO Study. AIDS 2000, 14:37–49.
58.Lee D, Mathews WC. Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy. Sixth conference on Retroviruses and Opportunustic Infections. Chicago, January–February 1999 [Abstract 644].
59.Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercie P, Valentin VD. Serum triglycerides, HIV Infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe D'Epidemiologie Clinique Du Sida En Aquitaine (GECSA). J Acquir Immune Defic Syndr 2000, 23:261–265.
60.Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000, 160:2050–2056.
61.Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994, 24: 416–420.
62.Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS 2001, 12:463–468.
63.Grunfeld C, Kotler, DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27–31.
64.Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, Dube MP. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001, 15:2001–2010.
65.Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13:2493–2505.
66.Carr A. An objective case definition of HIV lipodystrophy. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 31].
67.Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67:968–977.
68.McNamara JR, Leary ET, Ceriotti F, Boersma-Cobbaert CM, Cole TG, Hassemer DJ, et al. Point: status of lipid and lipoprotein standardization. Clin Chem 1997, 43:13006–13010.
69.Law M, Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, et al. Modelling the three year risk of myocardial infarction among participants in the D:A:D Study. Hiv Med 2003; 4(1):1–10.
Back to Top | Article Outline


DAD Steering Committee: Persons with * below (#: chair) and F. Houyez, T. Mertenskoetter, I. Weller.

DAD Central Coordination: N. Friis-Møller, C. Sabin, J.D. Lundgren.

DAD data managers: A. Sawitz and P. Ricks (coordination), M. Rickenbach, P. Pezzotti, E. Krum, R. Meester, V. Lavignolle, A. Sundström, B. Poll, E. Fontas, F. Torres, K. Petoumenos, J. Kjœr.

Back to Top | Article Outline

The members of the 11 Cohorts

ATHENA (AIDS Therapy Evaluation Project Netherlands)

Coordinating centre: F. de Wolf, J. Lange, E. van der Ven, H. Tissing, T. Hantke, R. Meester.

Participating physicians (city): W. Bronsveld (Alkmaar); H. Weigel, K. Brinkman, P. Frissen, J. ten Veen, M. Hillebrand, P. van Dam, S. Schieveld, J. Mulder, E. van Gorp, P. Meenhorst, A. van Eeden, S. Danner, F. Claessen, R. Perenboom, D. Blanckenberg, S. Blank, J. K. Eeftinck Schattenkerk, M. Godfried, S. Lowe, J. van der Meer, F. Nellen, K. Pogany, T. van der Poll, J. Prins, P. Reiss*, T. Ruys, M. van der Valk, A. Verbon, F. Wit (Amsterdam); C. Richter, R. van Leusen (Arnhem); R. Vriesendorp, F. Jeurissen (Den Haag); R. Kauffmann, E. Koger (Den Haag); B. Bravenboer (Eindhoven); C. ten Napel (Enschede); H.G. Sprenger, G. Law (Groningen); R.W. ten Kate (Haarlem); M. Leemhuis (Leeuwarden); F. Kroon, E. Schippers (Leiden); G. Schrey, S. van der Geest, A. van der Ven (Maastricht); P. Koopmans, M. Keuter, D. Telgt (Nijmegen); M. van der Ende, I. Gyssens, S. de Marie (Rotterdam); J. Juttmann, C. van der Heul (Tilburg); M. Schneider, J. Borleffs, L. Hoepelman, C. Jaspers, A. Matute, C. Schurink (Utrecht); W. Blok (Vlissingen).

Back to Top | Article Outline

Aquitaine (France)

Scientific committee: R. Salamon (chair), J. Beylot, M. Dupon, M. Le Bras, J.L. Pellegrin, J.M. Ragnaud; Coordinating centre staff: F. Dabis*, G. Chêne, N. Bernard, D. Lacoste, D. Malvy, D. Neau, M. Dupon, J.-F. Moreau, P. Morlat, P. Mercié, J.L. Pellegrin, J.M. Ragnaud, D. Commenges, H. Jacqmin-Gadda, R. Thiébaut, S. Lawson-Ayayi, V. Lavignolle, M.J. Blaizeau, M. Decoin, A.M. Formaggio, S. Delveaux, S. Labarerre, B. Uwamaliya, E. Vimard, L. Merchadou, G. Palmer, D. Touchard, D. Dutoit, F. Pereira, B. Boulant; Participating physicians (city): J. Beylot, P. Morlat, N. Bernard, M. Bonarek, F. Bonnet, B. Coadou, P. Gelie, D. Jaubert, C. Nouts, D. Lacoste, M. Dupon, H. Dutronc, G. Cipriano, S. Lafarie, J.Y. Lacut, J.L. Pellegrin, P. Mercie, J.F. Viallard, I. Faure, P. Rispal, C. Cipriano, B. Leng, M. Le Bras, F. Djossou, D. Malvy, J.P. Pivetaud, J.M. Ragnaud, C. De La Taille, D. Neau, T. Galperine, A. Ochoa, D. Chambon (Bordeaux).

Back to Top | Article Outline

AHOD (Australian HIV Observational Database, Australia)

Coordinating centre: M. Law*, K. Petoumenos (Sydney, New South Wales).

Participating sites (city, state): J. Anderson, J. Bal (Melbourne, Victoria), D. Austin, A. Gowers, D. Baker, R. McFarlane, A. Carr, D. Cooper (Sydney, New South Wales), J. Chuah, W. Fankhauser (Gold Coast, Queensland), S. Mallal, J. Skett (Perth, Western Australia), A. Mijch, K. Watson (Melbourne, Victoria), N. Roth, H. Wood (Melbourne, Victoria).

Back to Top | Article Outline

BASS (Spain)

Coordinating centre: G Calvo*, F Torres, S Mateu (Barcelona).

Participating physicians: P. Domingo, M.A. Sambeat, J. Gatell, E. Del Cacho (Barcelona), G. Sirera, G. Viñas (Badalona).

Back to Top | Article Outline

The Brussels St Pierre Cohort (Belgium)

N. Clumeck, S. De Wit*, M. Gerard, P. Hermans, M. Hildebrand, K. Kabeya, D. Konopnicki, M.C. Payen, B. Sommereijns, Y. Van Laethem.

Back to Top | Article Outline


Central coordination: J. Neaton, G. Bartsch*, W. El-Sadr, E. Krum, D. Wentworth.

Participating physicians (city, state): R. Luskin-Hawk (Chicago, Illinois), E. Telzak (Bronx, New York), D.I. Abrams (San Francisco, California), D. Cohn (Denver, Colorado), N. Markowitz (Detroit, Michigan), R. Arduino (Houston, Texas), D. Mushatt (New Orleans, Louisiana), G. Friedland (New Haven, Connecticut), G. Perez (Newark, New Jersey), E. Tedaldi (Philadelphia, Pennsylvania), E. Fisher (Richmond, Virginia), F. Gordin (Washington, DC), L.R. Crane (Detroit, Michigan), J. Sampson (Portland, Oregon), J. Baxter (Camden, New Jersey).

Back to Top | Article Outline

EuroSIDA Study Group (Multinational)

Central coordination: O Kirk*, A Mocroft, AN Phillips*, JD Lundgren*#.

Participating countries and physicians (city): Austria, N. Vetter (Vienna); Belgium, N. Clumeck, P. Hermans (Brussels), R. Colebunders (Antwerp); Czech Republic, L. Machala (Prague); Denmark, J. Nielsen, T. Benfield, J. Gerstoft, T. Katzenstein, B. Røge, P Skinhøj (Copenhagen), C. Pedersen (Odense); France, C. Katlama, J.-P. Viard (Paris), T. Saint-Marc, P. Vanhems (Lyon); Germany, M. Dietrich, C. Manegold, J. van Lunzen (Hamburg); V. Miller, S. Staszewski, M. Bieckel (Frankfurt), F.D. Goebel (Munich), B. Salzberger (Cologne), J. Rockstroh (Bonn); Greece, J. Kosmidis, P. Gargalianos, H. Sambatakou, J. Perdios, G. Panos, I. Karydis, A. Filandras (Athens); Hungary, D. Banhegyi (Budapest); Ireland, F. Mulcahy (Dublin); Israel, I Yust, D. Turner (Tel Aviv), S. Pollack, Z. Ben-Ishai (Haifa), Z. Bentwich (Rehovot), S. Maayan (Jerusalem); Italy, S. Vella, A. Chiesi (Rome), C. Arici (Bergamo), R. Pristerá (Bolzano), F. Mazzotta, A. Gabbuti (Florence), R. Esposito, A. Bedini (Modena), A. Chirianni, E. Montesarchio (Naples), V. Vullo, P. Santopadre, P. Narciso, A. Antinori, P. Franci, M. Zaccarelli (Rome), R. Finazzi (Milan); Luxembourg, R. Hemmer, T. Staub (Luxembourg); Norway, J. Bruun, A. Maeland, V. Ormaasen (Oslo); Poland, B. Knysz, J. Gasiorowski (Wroclaw), A. Horban (Warsaw), D. Prokopowicz (Bialystok), A. Boron-Kaczmarska, M. Pynka (Szczecin), M. Beniowski (Chorzow), H. Trocha (Gdansk); Portugal, F. Antunes, K. Mansinho, R. Proenca (Lisbon); Spain, J. González-Lahoz, B. Diaz, T. García-Benayas, L. Martin-Carbonero, V. Soriano (Madrid), B. Clotet, A. Jou, J. Conejero, C. Tural (Badalona), J.M. Miró (Barcelona); Sweden, A. Blaxhult, B. Heidemann, P. Pehrson (Stockholm); United Kingdom, M. Fisher (Brighton), R. Brettle (Edinburgh), S. Barton, A.M. Johnson, D. Mercey, C. Loveday, M.A. Johnson, A. Pinching, J. Parkin, J. Weber, G. Scullard (London).

Back to Top | Article Outline

HivBivus (Sweden)

Central coordination: L. Morfeldt*, G. Thulin, A. Sundström.

Participating physicians (city): B. Åkerlund (Huddinge), K. Koppel, A. Karlsson (Stockholm), L. Flamholc, C. Håkangård (Malmö).

Back to Top | Article Outline

ICONA (Italy)

Central coordination: A. D'Arminio Monforte*, P. Pezzotti.

Participarting physicians: M. Moroni, A. d'Arminio Monforte, A. Cargnel, S. Merli, G.M. Vigevani, C. Pastecchia, A. Lazzarin, R. Novati, L. Caggese, C. Moioli (Milano), M.S. Mura, G. Madeddu (Sassari), F. Suter, C. Arici (Bergamo), P.E. Manconi (Cagliari), F. Mazzotta (Firenze), A. Poggio, G. Bottari (Verbania), G. Pagano, A. Alessandrini (Genova), A. Scasso, A. Vincenti (Lucca), V. Abbadesse, S. Mancuso (Palermo), F. Alberici, M. Sisti (Piacenza), M. Arlotti, P. Ortolani (Rimini), F. De Lalla, G. Tositti (Vicenza), N. Piersantelli, R. Piscopo (Genova), E. Raise, S. Pasquinucci (Venezia), F. Soscia, L. Tacconi (Latina), U. Tirelli, G. Nasti (Aviano) E. Rinaldi, L. Pusterla (Como), G. Carosi, F. Castelli (Brescia), G. Cadeo, D. Vangi (Brescia), G. Carnevale, D. Galloni (Cremona), G. Filice, R. Bruno (Pavia), A. Sinicco, M. Sciandra, P. Caramello, L. Gennero, M.L. Soranzo, A. Macor (Torino), G. Rizzardini, C. Abeli (Busto Arsizio), F. Chiodo, V. Colangeli (Bologna), L. Bonazzi, M. Ursitti (Reggio Emilia), F. Menichetti, A. Smorfa (Pisa), R. Esposito, C. Mussini (Modena), F. Ghinelli, L. Sighinolfi (Ferrara), F. Gritti, O. Coronado (Bologna), T. Zauli, G. Ballardini (Ravenna), M. Montroni, A. Costantini (Ancona), E. Petrelli, A. Cioppi (Pesaro), L. Ortona, A. De Luca, N. Petrosillo, P. Noto, P. Narciso, G. D'Offizi, A. Antinori, P. De Longis, V Vullo, M. Lichtner (Roma), G. Pastore, M.L. Perulli (Bari), A. Chirianni, L. Loiacono, M. Piazza, S. Nappa, N. Abrescia, M. De Marco (Napoli), A. Colomba, T. Prestileo (Palermo), C. De Stefano, A. La Gala (Potenza), T. Ferraro, A. Scerbo (Catanzaro), P. Grima, P. Tundo (Lecce), E. Pizzigallo, F. Ricci (Chieti), B. Grisorio, S. Ferrara (Foggia).

Back to Top | Article Outline

Nice Cohort (France)

Central coordination: C. Pradier*, E. Fontas, C. Caissotti.

Participating physicians: P. Dellamonica, L. Bentz, E. Bernard, S. Chaillou, F. De Salvador-Guillouet, J. Durant, R. Guttman, L. Heripret, V. Mondain-Miton, I. Perbost, B. Prouvost-Keller, P. Pugliese, V. Rahelinirina, P.M. Roger, F. Vandenbos.

Back to Top | Article Outline

SHCS (The Swiss HIV Cohort Study, Switzerland)

Scientific Committee: R. Amiet, M. Battegay (chair), E. Bernasconi, H. Bucher, P. Bürgisser, M. Egger, P. Erb, W. Fierz, M. Flepp, P. Francioli, H. J. Furrer, M. Gorgievski, H. Günthard, P. Grob, B. Hirschel, C. Kind, T. Klimkait, B. Ledergerber, U. Lauper, M. Opravil, F. Paccaud, G. Pantaleo, L. Perrin, W. Pichler, J. C. Piffaretti, M. Rickenbach, C. Rudin, P. Sudre, V. Schiffer, J. Schupbach, A. Telenti, P. Vernazza, R. Weber*.

Participating physicians (city): H. C. Bucher, M. Battegay (Basel), H. J. Furrer, M. Egger (Bern), A. Calmy, B. Hirschel (Geneve), A. Telenti (Lausanne), E. Bernasconi, L. Magenta (Lugano), T. Wagels, P. Vernazza (St. Gall), M. Flepp, R. Weber (Zürich).


antiretroviral therapy; cardiovascular disease; adverse effects; cohort study; hyperlipidaemia; prevalence; risk factors

© 2003 Lippincott Williams & Wilkins, Inc.